Orforglipron + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Peripheral Arterial Disease
Conditions
Peripheral Arterial Disease
Trial Timeline
Oct 31, 2025 → Jun 1, 2028
NCT ID
NCT07223593About Orforglipron + Placebo
Orforglipron + Placebo is a phase 3 stage product being developed by Eli Lilly for Peripheral Arterial Disease. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07223593. Target conditions include Peripheral Arterial Disease.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (20)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07241390 | Phase 3 | Recruiting |
| NCT07223593 | Phase 3 | Recruiting |
| NCT07202884 | Phase 3 | Recruiting |
| NCT07153471 | Phase 3 | Recruiting |
| NCT06972472 | Phase 3 | Recruiting |
| NCT06972459 | Phase 3 | Recruiting |
| NCT06993792 | Phase 3 | Recruiting |
| NCT06952530 | Phase 3 | Recruiting |
| NCT06948435 | Phase 3 | Recruiting |
| NCT06948422 | Phase 3 | Recruiting |
| NCT06824051 | Phase 1 | Completed |
| NCT06672939 | Phase 3 | Recruiting |
| NCT06672549 | Phase 3 | Recruiting |
| NCT06649045 | Phase 3 | Active |
| NCT06584916 | Phase 3 | Completed |
| NCT06109311 | Phase 3 | Completed |
| NCT05971940 | Phase 3 | Completed |
| NCT05931380 | Phase 3 | Completed |
| NCT05869903 | Phase 3 | Active |
| NCT05872620 | Phase 3 | Completed |
Competing Products
20 competing products in Peripheral Arterial Disease